

July 2024



In EMEA for Professional Clients (MiFID Directive 2014/65/EU Annex II) only. In Switzerland for Qualified Investors (Art. 10 Para. 3 of the Swiss Federal Collective Investment Schemes Act (CISA)). In APAC and LATAM for institutional investors only. Further distribution of this material is strictly prohibited. In Australia and New Zealand: for Wholesale Investors only. In MENA(including Qatar): for professional Clients. Further distribution of this material is strictly prohibited. For business customers only. For

# Breaking down the data

Summary of findings from the 2023 Statutory Filings and investment considerations for U.S. insurers

While the Statutory Filings data represent the aggregate of insurance company general account assets invested in 2023, it is important to keep in mind what was taking place, both geopolitically and capital markets, that could have influenced some of the decision-making process. From 2022 into 2023, interest rates were increasing rapidly, inflation was spiking, supply chain issues remained, and geopolitical unrest mounting. This continued to play out for most of last year, with attention shifting to when the U.S. Federal Reserve was going to pivot on its interest-rate stance and if the United States was going to enter a recession.

# **Overall Highlights**

Net investment income earned increased significantly in 2023, for both U.S. Life insurers and P&C insurers (ex-Berkshire Hathaway), up 9.6% (to a new high of \$225.25 billion) and up 27.7% (to \$59.1 billion), respectively.

A number of long-standing trends that began years earlier from the low interest rate environment remained prominent, namely allocations to certain less correlated alternative asset classes such as the move to Schedule BA assets, Structured Securities, and private markets in general.

Broadly speaking, from an overall allocation perspective among Life, P&C and Healthcare companies, insurers' weighting toward bonds marginally decreased, but nothing substantial. The more significant move, however, could be seen in duration and credit positioning. Our analysis indicates this can be attributed to how insurers have chosen to position portfolios in the rising-rate environment, either opting to increase cash holdings until determining when to extend duration or locking in higher yields by extending the duration with high-quality assets.

#### **Fixed Income**

Based on SNL year-end 2023 data


Summary			
	P&C	Life	Health
Cash	=		•
Duration ex Cash	•	1	1
Credit Quality	•	1	1
Biggest Increases	Agency RMBS Corporates ABS (excl. CLO)	ABS (excl. CLO) CLO	Agency RMBS Treasuries
Biggest Decreases	Municipals Treasuries	Corporates Non-Agency CMBS	Bond Funds Non-Agency CMBS


For Institutional Investor and Registered Representative use only. Not to be shared with the public. Further distribution of this material is strictly prohibited. Past performance is not indicative of future results. No assurance can be given that any forecast or target will be achieved.

Looking at the fixed income securities bought and sold throughout 2023, we were able to identify certain similarities and differences across industries. On average, insurers increased the duration in their portfolios and enhanced the credit quality while still holding cash on the sidelines. Across industries, Agency RMBS was used mainly to increase the duration of the portfolio, picking up yield compared to Treasuries while possibly exposing the portfolio to convexity risks that would need to be managed. While the relative allocation in Agency RMBS for Life remained flat and allocation shifts from Corporates to Structured Securities, such as ABS and CLO, were duration neutral, P&C companies decreased their (since years falling) municipal bond allocation further and Health companies mainly decreased their (mostly short duration) bond fund holdings.


While the average maturity of bond portfolios increased, the maturity profile is very industry specific and can be seen in the graphs below. In general, we see most investments on the curve at 5-, 10- and 30-years, with P&C also utilizing the 7-year spot.


# Maturity Distribution ex-Cash for P&C





### Maturity Distribution ex-Cash for Life







Source: SNL YE2023 Data

For Institutional Investor and Registered Representative use only. Not to be shared with the public. Further distribution of this material is strictly prohibited. Past performance is not indicative of future results. No assurance can be given that any forecast or target will be achieved.

## Maturity Distribution ex-Cash for Health





Source: SNL YE2023 Data

Along these lines there also appeared to be a migration toward higher-rated investment-grade bonds with NAIC 1 designations, and away from NAIC 2 and below. While DWS thinks it is too early to signal this a "trend," it is something worth watching especially if, and when, the Fed begins lowering interest rates and income profiles changes.

This general shift toward higher credit quality is implemented different across industries. While a reduction of BBB and below holds true for all industries, Health and P&C favor NAIC 1.A securities more than Life, which is a result of the increase in Agency RMBS allocations.

ΛI	location	(110	202	OVE)
AΠ	location	۱۷S.	ZUZ	ZYEI

	De C	1:5-	11146
	P&C	Life	Health
AAA (incl. U.S. Government)	40.2% (2.1%)	18.5% (0.0%)	44.3% (2.2%)
AA	15.5% <mark>(-1.6%)</mark>	11.3% (0.6%)	10.0% (-0.2%)
A	21.1% (0.3%)	28.9% (1.1%)	20.5% (-0.4%)
BBB	18.7% <mark>(-0.6%)</mark>	36.2% (-1.4%)	19.8% (-0.8%)
ВВ	2.2% (-0.2%)	3.2% (-0.3%)	3.3% (-0.3%)
В	1.8% (-0.1%)	1.4% (0.0%)	1.8% (-0.3%)
CCC & Below	0.5% (0.1%)	0.5% (0.0%)	0.3% (-0.3%)

Source: SNL Data 2023, based on NAIC designations

#### Real Estate

Within mortgage-backed securities, we observed a stable split between commercial and residential real estate, where commercial dominated residential for non-agency issues. However, in recent years we noticed a fast-increasing share of Residential Mortgage-Backed Securities compared to Commercial Mortgage-Backed Securities. The team views this in the context of the COVID office difficulties and see this as the industry becoming more discerning and savvier about the sectoral composition of the real estate market in both public and private assets. For private strategies, this might also mean exploring sector strategies even if they ultimately adhere to ODCE strategies (which, anecdotally, is something we are tending to hear from investors currently with the Office bottom potentially in sight). We remain cautious in the near-term as it relates to Office investments, however, our DWS Real Estate Research team is more optimistic toward Industrial and Retail sectors among commercial properties.

# Schedule BA

Another notable observation is among Schedule BA assets. While Life, P&C and Health companies all maintained allocations to private assets, the composition among different insurance types appears to be changing; another way to express that is certain private asset classes might be in vogue compared to others depending on insurance company type. And while the overall allocation to Schedule BA assets was steady when comparing 2023 to 2022, our view is that the momentum seen over the past few years was likely tempered due to the availability of public bond income in the market. Based on interactions with investors, however, we do not anticipate this reversing course. Despite relative spread benefits coming down, these investments still maintain high levels of diversification, positive accounting volatility benefits, and opportunities to participate in the origination process.

#### Other trends that could remain in focus

For municipal bonds, the team thinks the downward trend (most notably in the P&C industry) will likely continue unless we see corporate tax increases, which currently seems unlikely. Taxable municipals can make sense in a portfolio context, especially to cover longer duration liabilities, but we do not foresee major increases in insurer portfolios.

The increase in Structured Products, mainly ABS, appears to have "more room to grow," given their strong performance, attractive yields, and diversification benefits. CLOs were traditionally a growth driver for ABS allocations, but we saw stagnating, even slightly decreasing, allocations in P&C and Health portfolios, while Life insurers continued to increase their already larger allocation. It remains to be seen how future developments by the NAIC and economic impacts change the appetite for CLOs.

Also, the team believes credit positioning will continue to be important. High yield and BBB securities can potentially be beneficial for a portfolio, but there are increased opportunities to obtain yields with less risk currently. Additionally, the efficient frontier has not significantly steepened as spreads are comparably tight, which might lead insurers to re-evaluate their risk tolerance and invest more conservatively in their bond portfolios. Private alternatives however are "here to stay," and we expect this area to grow, although more nuanced and not at the same rate as in previous years.

Duration positioning will likely remain a significant challenge especially as it pertains to when the market might see a Fed pivot. Higher interest rates for a longer period can have unintended consequences, including risks to financial stability, potentially leading to rapid rate cuts to support the economy. But if inflation remains high due to economic momentum, rate cuts may be delayed (there is always the possibility of an increase as well, although that is not being forecast). This makes positioning a nuanced topic, where liability structure, key rate durations, and convexities, especially when using securitized products to extend duration, should be considered. We will probably continue to see insurers adopting both approaches until the picture becomes clearer because right now it often implies an active bet on rates or at least an acceptance of downside risk.

For Institutional Investor and Registered Representative use only. Not to be shared with the public. Further distribution of this material is strictly prohibited. Past performance is not indicative of future results. No assurance can be given that any forecast or target will be achieved.

#### Contributors

Jan Bilstein

Senior Manager Insurance Structuring & Solutions-Americas Ryan Hassey

Manager Insurance Structuring & Solutions-Americas Anthony Lupa

Senior Manager Insurance Structuring & Solutions-Americas

# Important information

For Institutional Investor and Registered Representative use only. Further distribution is strictly prohibited.

Bond investments are subject to interest rate, credit, liquidity and market risks to varying degrees. When interest rates rise, bond prices generally fall. Credit risk refers to the ability of an issuer to make timely payments of principal and interest.

Bond and loan investments are subject to interest-rate, credit, liquidity and market risks to varying degrees. When interest rates rise, bond prices generally fall. Credit risk refers to the ability of an issuer to make timely payments of principal and interest. Floating rate loans tend to be rated below-investment grade and may be more vulnerable to economic or business changes than issuers with investment-grade credit. Bond investments are subject to interest-rate, credit, liquidity and market risks to varying degrees. When interest rates rise, bond prices generally fall. Credit risk refers to the ability of an issuer to make timely payments of principal and interest.

Loan investments are subject to interest-rate, credit, liquidity and market risks to varying degrees. Floating rate loans tend to be rated below-investment grade and may be more vulnerable to economic or business changes than issuers with investment-grade credit.

Investments in lower-quality ("junk bonds") and non-rated securities present greater risk of loss than investments in higher-quality securities.

Mortgage-backed securities represent interests in "pools" of mortgages and often involve risks that are different from or possibly more acute than risks associated with other types of debt instruments. When market interest rates increase, the market values of mortgage-backed securities decline and volatility of the fund may increase. When market interest rates decline, the value of mortgage-backed securities may increase, but could expose the fund to a lower rate of return on investment.

Municipal securities are subject to the risk that litigation, legislation or other political events, local business or economic conditions or the bankruptcy of the issuer could have a significant effect on an issuer's ability to make payments of principal and/or interest. The market for municipal bonds may be less liquid than for taxable bonds and there may be less information available on the financial condition of issuers of municipal securities than for public corporations.

Index performance is shown for illustrative purposes only and is not intended to represent historical or to predict future performance of any specific investment or DWS's. DWS products may have experienced negative performance over these time periods. Past performance is not indicative of future results. Investments are subject to risk, including possible loss of investment capital.

The comments, opinions and estimates contained herein are for informational purposes only and sets forth our views as of this date. The underlying assumptions and these views are subject to change without notice. Past performance or any prediction or forecast is not indictive of futures results. No assurance can be given that any forecast or target will be achieved.

The material was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. It is intended for informational purposes only and it is not intended that it be relied on to make any investment decision. It is for professional investors only. It does not constitute investment advice or a recommendation or an offer or solicitation and is not the basis for any contract to purchase or sell any security or other instrument, or for DWS and its affiliates to enter into or arrange any type of transaction as a consequence of any information contained herein.

Please note that this information is not intended to provide tax or legal advice and should not be relied upon as such. DWS does not provide tax, legal or accounting advice. Please consult with your respective experts before making investment decisions.

Neither DWS nor any of its affiliates, gives any warranty as to the accuracy, reliability or completeness of information which is contained. Except insofar as liability under any statute cannot be excluded, no member of DWS, the Issuer or any officer, employee or associate of them accepts any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission or for any resulting loss or damage whether direct, indirect, consequential or otherwise suffered.

This document is intended for discussion purposes only and does not create any legally binding obligations on the part of DWS and/or its affiliates. Without limitation, this document does not constitute investment advice or a recommendation or an offer or solicitation and is not the basis for any contract to purchase or sell any security or other instrument, or for DWS to enter into or arrange any type of transaction as a consequence of any information contained herein. The information contained in this document is based on material we believe to be reliable; however, we do not represent that it is accurate, current, complete, or error free. Assumptions, estimates and opinions contained in this document constitute our judgment as of the date of the document and are subject to change without notice. Past performance is not a guarantee of future results. Any forecasts provided herein are based upon our opinion of the market as at this date and are subject to change, dependent on future changes in the market. Any prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets is not necessarily indicative of the future or likely performance. Investments are subject to risks, including possible loss of principal amount invested.

War, terrorism, sanctions, economic uncertainty, trade disputes, public health crises and related geopolitical events have led and in the future may lead to significant disruptions in US and world economies and markets, which may lead to increased market volatility and may have significant adverse effects on the fund and its investments.

For investors in Bermuda: This is not an offering of securities or interests in any product. Such securities may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, non-Bermudian persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation.

DWS is the brand name of DWS Group GmbH & Co. KGaA and its subsidiaries under which they do business. The DWS legal entities offering products or services are specified in the relevant documentation. DWS, through DWS Group GmbH & Co. KGaA, its affiliated companies and its officers and employees (collectively "DWS") are communicating this document in good faith and on the following basis.

This document is for information/discussion purposes only and does not constitute an offer, recommendation or solicitation to conclude a transaction and should not be treated as investment advice.

This document is intended to be a marketing communication, not a financial analysis. Accordingly, it may not comply with legal obligations requiring the impartiality of financial analysis or prohibiting trading prior to the publication of a financial analysis.

This document contains forward looking statements. Forward looking statements include, but are not limited to assumptions, estimates, projections, opinions, models and hypothetical performance analysis. No representation or warranty is made by DWS as to the reasonableness or completeness of such forward looking statements. Past performance is no guarantee of future results.

The information contained in this document is obtained from sources believed to be reliable. DWS does not guarantee the accuracy, completeness or fairness of such information. All third party data is copyrighted by and proprietary to the provider. DWS has no obligation to update, modify or amend this document or to otherwise notify the recipient in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate.

Investments are subject to various risks. Detailed information on risks is contained in the relevant offering documents.

No liability for any error or omission is accepted by DWS. Opinions and estimates may be changed without notice and involve a number of assumptions which may not prove valid.

DWS does not give taxation or legal advice.

This document may not be reproduced or circulated without DWS's written authority.

This document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, including the United States, where such distribution, publication, availability or use would be contrary to law or regulation or which would subject DWS to any registration or licensing requirement within such jurisdiction not currently met within such jurisdiction. Persons into whose possession this document may come are required to inform themselves of, and to observe, such restrictions

## © 2024 DWS International GmbH /DWS Investment GmbH

Issued in the UK by DWS Investments UK Limited which is authorised and regulated in the UK by the Financial Conduct Authority.

#### © 2024 DWS Investments UK Limited

In Hong Kong, this document is issued by DWS Investments Hong Kong Limited. The content of this document has not been reviewed by the Securities and Futures Commission.

# © 2024 DWS Investments Hong Kong Limited

In Singapore, this document is issued by DWS Investments Singapore Limited. The content of this document has not been reviewed by the Monetary Authority of Singapore.

#### © 2024 DWS Investments Singapore Limited

In Australia, this document is issued by DWS Investments Australia Limited (ABN: 52 074 599 401) (AFSL 499640). The content of this document has not been reviewed by the Australian Securities and Investments Commission.

#### © 2024 DWS Investments Australia Limited

In Latin America, for institutional investors only. Further distribution of this material is strictly prohibted.

For Investors in Canada: No securities commission or similar authority in Canada has reviewed or in any way passed upon this document or the merits of the securities described herein and any representation to the contrary is an offence. This document is intended for discussion purposes only and does not create any legally binding obligations on the part of DWS Group. Without limitation, this document does not constitute an offer, an invitation to offer or a recommendation to enter into any transaction. When making an investment decision, you should rely solely on the final documentation relating to the transaction you are considering, and not the [document – may need to identify] contained herein. DWS Group is not acting as your financial adviser or in any other fiduciary capacity with respect to any transaction presented to you. Any transaction(s) or products(s) mentioned herein may not be appropriate for all investors and before entering into any transaction you should take steps to ensure that you fully understand such transaction(s) and have made an independent assessment of the appropriateness of the transaction(s) in the light of your own objectives and circumstances, including the possible risks and benefits of entering into such transaction. You should also consider seeking advice from your own advisers in making this assessment. If you decide to enter into a transaction with DWS Group you do so in reliance on your own judgment. The information contained in this document is based on material we believe to be reliable; however, we do not represent that it is accurate, current, complete, or error free. Assumptions, estimates and opinions contained in this document constitute our judgment as of the date of the document and are subject to change without notice. Any projections are based on a number of assumptions as to market conditions and there can be no guarantee that any projected results will be achieved. Past performance is not a guarantee of future results. The distribution of this document and avail

DWS Distributors, Inc. 222 S. Riverside Plaza, 34<sup>th</sup> Floor Chicago, IL 60606-5808 USA

The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries such as DWS Distributors, Inc. which offers investment products or DWS Investment Management Americas Inc. and RREEF America L.L.C. which offer advisory services.

© 2024 DWS Group GmbH & Co. KGaA. All rights reserved. I-101976-1 (7/24)